Jan 09, 2020 - Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Jan 09, 2020 - Merck's (MRK) Keytruda gets FDA's approval to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Jan 08, 2020 - Keytruda is now permitted for use in treating an aggressive form of bladder cancer.
Jan 08, 2020 - Finally some good news from the American Cancer Society.
Jan 08, 2020 - Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
Jan 07, 2020 - The star cancer immunotherapy missed an important endpoint during a study with small cell lung cancer.
Jan 07, 2020 - Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Dec 31, 2019 - AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
Dec 27, 2019 - The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Dec 24, 2019 - FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine.